Evidence map›Paper›PMID 28971346›Full record

ArticleMolecular imaging and biology2018

Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany.

D L Bailey, B J Pichler, B Gückel, G Antoch, H Barthel, Z M Bhujwalla, S Biskup, S Biswal, M Bitzer, R Boellaard and 26 more

Open access · hybridAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system.European journal of nuclear medicine and molecular imaging · 2021
    Article
  9. Article
  10. Article
  11. What scans we will read: imaging instrumentation trends in clinical oncology.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020
    Review
  12. Advances in simultaneous PET/MR for imaging neuroreceptor function.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Molecular Imaging of Diabetic Foot Infections: New Tools for Old Questions.International journal of molecular sciences · 2019
    Review
  20. Towards quantitative [18F]FDG-PET/MRI of the brain: Automated MR-driven calculation of an image-derived input function for the non-invasive determination of cerebral glucose metabolic rates.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 11 countries.

D L BaileyDepartment of Nuclear Medicine, Royal North Shore Hospital, and Faculty of Health Sciences, University of Sydney, Sydney, Australia.
B J PichlerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls-Universität, Tübingen, Germany.
B GückelDepartment of Diagnostic and Interventional Radiology, University of Tübingen, Tübingen, Germany.
G AntochDepartment of Diagnostic and Interventional Radiology, Medical Faculty, University Dusseldorf, 40225, Dusseldorf, Germany.
H BarthelDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
Z M BhujwallaDivision of Cancer Imaging Research, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
S BiskupPraxis für Humangenetik Tübingen, Paul-Ehrlich-Str. 23, 72076, Tübingen, Germany.
S BiswalMolecular Imaging Program at Stanford (MIPS) and Bio-X, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
M BitzerDepartment of Internal Medicine I, Eberhard-Karls University, Tübingen, Germany.
R BoellaardDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
R F BrarenInstitute of Diagnostic and Interventional Radiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
C BrendleDiagnostic and Interventional Neuroradiology, Department of Radiology, Eberhard Karls University, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
K BrindleCancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
A ChitiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
C la FougèreDepartment of Radiology, Nuclear Medicine and Clinical Molecular Imaging, Eberhard-Karls-Universität, Tübingen, Germany.
R GilliesDepartment of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33621, USA.
V GohCancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.
M GoyenGE Healthcare GmbH, Beethovenstrasse 239, Solingen, Germany.
M HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
L HeukampNew Oncology GmbH, Köln, Germany.
G M KnudsenNeurobiology Research Unit, Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
A M KrackhardtIII. Medical Department, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
I LawDepartment of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
J C MorrisKnight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO, USA.
K NikolaouDepartment of Diagnostic and Interventional Radiology, University of Tübingen, Tübingen, Germany.
J NuytsNuclear Medicine & Molecular Imaging, KU Leuven, Leuven, Belgium.
A A OrdonezDepartment of Pediatrics, Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
K PantelInstitute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
H H QuickHigh Field and Hybrid MR Imaging, University Hospital Essen, Essen, Germany.
K RiklundDepartment of Radiation Sciences, Umea University, Umea, Sweden.
O SabriDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
B SattlerDepartment of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany.
E G C TroostOncoRay-National Center for Radiation Research in Oncology, Dresden, Germany.
M ZaissHigh Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Tübingen, Germany.
L ZenderDepartment of Internal Medicine VIII, University Hospital Tübingen, Tübingen, Germany.
Thomas BeyerQIMP Group, Center for Medical Physics and Biomedical Engineering General Hospital Vienna, Medical University Vienna, 4L, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.beyer@meduniwien.ac.at.
University of Tübingen · DEUniversity Hospital Leipzig · DEJohns Hopkins University · USTUM Klinikum · DEUniversity of Copenhagen · DKErwin L. Hahn Institute for Magnetic Resonance Imaging · DEHeinrich Heine University Düsseldorf · DEHelmholtz-Zentrum Dresden-Rossendorf · DEHumanitas University · ITKU Leuven · BEMax Planck Institute for Biological Cybernetics · DEMedical University of Vienna · ATMoffitt Cancer Center · USPraxis für Humangenetik Tübingen · DESiemens (Germany) · DEStanford University · USSt Thomas' Hospital · GBThe University of Sydney · AUUmeå University · SEUniversität Hamburg · DE

Funding

Cancer Research UK 16463Cancer Research UK 17242Cancer Research UK 20000
6 · The paper itself

Abstract

The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.

Indexed as

Magnetic Resonance ImagingPositron-Emission TomographyHumansLiquid BiopsyRadiotherapy, Image-GuidedTumor MicroenvironmentHybrid imagingInfectionInflammationMolecular imagingMRIMR-PETMulti-parametric imagingNeurologyOncologyPETPET/CTPET/MRIQuantification

Identifiers

PMID28971346
PMCPMC5775351
OpenAlexW2762433036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.